Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells

Biochemical and Biophysical Research Communications

Volumn 358, Issue 1, 2007, Pages 226-232

  Tamura, Shinichi ^a   Hosoi, Hajime ^a   Kuwahara, Yasumichi ^a   Kikuchi, Ken ^a   Otabe, Osamu ^a   Izumi, Moriatsu ^a   Tsuchiya, Kunihiko ^a   Iehara, Tomoko ^a   Gotoh, Takahiro ^a   Sugimoto, Tohru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; Epidermal growth factor receptor; Gefitinib; Neuroblastoma

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL GROWTH; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEUROBLASTOMA; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34248164103     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.124     Document Type: Article

References (20)

1. In: Brodeur G.M., Sawada T., Tsuchida Y., and Voute P.A. (Eds). Neuroblastoma (2000), Elsevier Science Publishers B.V., Amsterdam
2. Bennasroune A., Gardin A., Aunis D., Cremel G., and Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol. Hematol. 50 (2004) 23-38
3. Meco D., Riccardi A., Servidei T., Brueggen J., Gessi M., Riccardi R., and Dominici C. Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett. 228 (2005) 211-219
4. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002) 5749-5754
5. Nicholson R.I., Gee J.M.W., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 (2001) S9-S15
6. Mirkin B.L., Clark S.H., and Zhang C. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Prolif. 35 (2002) 105-115
7. Ho R., Minturn J.E., Hishiki T., Zhao H., Wang Q., Cnaan A., Maris J., Evans A.E., and Brodeur G.M. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 65 (2005) 9868-9875
8. Osone S., Hosoi H., Kuwahara Y., Matsumoto Y., Iehara T., and Sugimoto T. Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int. J. Cancer 112 (2004) 219-224
9. Kuwahara Y., Hosoi H., Osone S., Kita M., Iehara T., Kuroda H., and Sugimoto T. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin. Cancer Res. 10 (2004) 5940-5948
10. Junttila T.T., Laato M., Vahlberg T., Soderstrom K.O., Visakorpi T., Isola J., and Elenius K. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin. Cancer Res. 9 (2003) 5346-5357
11. Magné N., Fischel J.L., Tiffon C., Formento P., Dubreuil A., Renee N., Formento J.L., Francoual M., Ciccolini J., Etienne M.C., and Milano G. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br. J. Cancer 89 (2003) 585-592
12. Moasser M.M., Basso A., Averbuch S.D., and Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER-2-driven signaling and suppresses the growth of HER-2overexpressing tumor cells. Cancer Res. 61 (2001) 7184-7188
13. Magné N., Fischel J.L., Dubreuil A., Formento P., Poupon M.F., Laurent-Puig P., and Milano G. Influence of epidermal growth factor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839. Br. J. Cancer 86 (2002) 1518-1523
14. Chang G.C., Hsu S.L., Tsai J.R., Liang F.P., Lin S.Y., Sheu G.T., and Chen C.Y. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem. Pharmacol. 68 (2004) 1453-1464
15. Piechocki M.P., Yoo G.H., Dibbley S.K., Amjad E.H., and Lonardo F. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int. J. Cancer 119 (2006) 441-454
16. van Noesela M.M., and Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre'. Gene 325 (2004) 1-15
17. Nakagawa K., Tamura T., Negoro S., Kudoh S., Yamamoto N., Yamamoto N., Takeda K., Swaisland H., Nakatani I., Hirose M., Dong R.P., and Fukuoka M. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14 (2003) 922-930
18. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., and Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa™), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6 (2000) 2053-2063
19. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000) 4885-4892
20. Van Schaeybroeck S., Kyula J., Kelly D.M., Karaiskou-McCaul A., Stokesberry S.A., Van Cutsem E., Longley D.B., and Johnston P.G. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol. Cancer Ther. 5 (2006) 1154-1165